Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sabine, Brutlach"'
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called
Autor:
John T. Hamm, Xiuning Le, Sabine Brutlach, Suman Rao, Barbara Ellers-Lenz, Omkar Subhash Marathe, Christine M. Bestvina, Joshua K. Sabari, Viola W. Zhu, Ronald J. Scheff, Jonathan Thompson, Umit Tapan, Niki Karachaliou, Philip E. Lammers, Egbert F. Smit, Melissa Lynne Johnson, Yi-Long Wu, Luis E. Raez, Gilberto Lopes
Publikováno v:
Journal of Clinical Oncology. 39:TPS9136-TPS9136
TPS9136 Background: METamp is a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). METamp occurs in ̃30% of patients who progress on EGFR TKI therapy as measured using fluorescence in situ hybridization (FISH). There is an u